文献速递甲状腺疾病

使用碘塞罗宁联合或不联合左甲状腺素与单用左甲状腺素者的心力衰竭和卒中风险:倾向评分匹配分析

Heart Failure and Stroke Risks in Users of Liothyronine With or Without Levothyroxine Compared with Levothyroxine Alone: A Propensity Score-Matched Analysis.
PubMed 文献 · Thyroid · 2022-06-07

该回顾性多中心研究基于四个医院数据库的观察性医疗结果合作项目通用数据模型,比较使用碘塞罗宁(LT3)至少90天者与单用左甲状腺素(LT4)者的长期安全性。经1:4倾向评分匹配后,LT3使用者的心力衰竭(IRR=1.664,95%CI 1.002-2.764,p=0.049)和卒中(IRR=1.757,95%CI 1.073-2.877,p=0.025)风险高于单用LT4者。

要点

  • LT3使用者心力衰竭风险高于单用LT4者(IRR=1.664,95%CI 1.002-2.764,p=0.049)。
  • LT3使用者卒中风险高于单用LT4者(IRR=1.757,95%CI 1.073-2.877,p=0.025)。
  • 有甲状腺癌病史且LT3治疗≥52周者心力衰竭风险更高,无甲状腺癌病史且LT3治疗≥52周者卒中风险更高。

核心结论

  • LT3使用与较长使用时间和有甲状腺癌病史患者的心力衰竭和卒中发生率增加相关。
  • 临床医生应考虑长期使用LT3的甲状腺癌患者的心力衰竭和卒中风险。
  • 这些发现需要在其他人群中确认。

研究设计与样本

  • 回顾性多中心研究,覆盖四个医院数据库,编码为观察性医疗结果合作项目(OMOP)通用数据模型(CDM)。
  • LT3使用者定义为接受LT3处方至少90天者(联合或不联合LT4),与单用LT4者经1:4倾向评分匹配后比较安全性结局。
  • 共识别1434例LT3使用者和3908例单用LT4者。

主要发现

  • LT3使用者与单用LT4者的安全性结局发生率存在统计学显著差异。
  • LT3使用者心力衰竭风险高于单用LT4者(IRR=1.664,95%CI 1.002-2.764,p=0.049)。
  • LT3使用者卒中风险高于单用LT4者(IRR=1.757,95%CI 1.073-2.877,p=0.025)。
  • 亚组分析显示,有甲状腺癌病史的LT3使用者及接受LT3治疗≥52周者心力衰竭风险更高。
  • 无甲状腺癌病史的LT3使用者及接受LT3治疗≥52周者卒中风险更高。

临床怎么用

  • 作者认为,临床医生应考虑长期使用LT3的甲状腺癌患者的心力衰竭和卒中风险。
  • 作者指出这些发现需要在其他人群中确认。

局限性

  • 原文指出这些发现需要在其他人群中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Combination therapy with liothyronine (LT3) and levothyroxine (LT4) is used in patients with persistent symptoms, despite being administered an adequate dose of LT4. LT3 may also be used in some thyroid cancer patients preparing for radioactive iodine therapy. However, there is a controversy regarding the safety of LT3 use, and there has been no definite evidence of long-term safety of LT3 therapy in Asian populations. The aim of this study was to examine the long-term safety of LT3 therapy using the Common Data Model (CDM). Methods: We conducted a retrospective multicenter study across four hospital databases encoded in the Observational Medical Outcomes Partnership (OMOP) CDM. LT3 users were defined as those who received an LT3 prescription for at least 90 days (with or without LT4), and their safety outcomes were compared with those in LT4-only users after 1:4 propensity score matching. Safety outcomes included the incidences of osteoporosis, cardiovascular disease, cancer, anxiety disorder, and mood disorder. Results: We identified 1434 LT3 users and 3908 LT4-only users. There was a statistically significant difference in the incidence rate of safety outcomes between LT3 users and LT4-only users. The risks of heart failure (incidence rate ratio [IRR] = 1.664, 95% confidence interval [95% CI] 1.002-2.764, p = 0.049) and stroke (IRR = 1.757, CI 1.073-2.877, p = 0.025) were higher in LT3 users than in LT4-only users. When subgroup analysis was performed according to the presence/absence of thyroid cancer history and duration of thyroid hormone replacement, the risk of heart failure was higher in LT3 users with a history of thyroid cancer and those who underwent ≥52 weeks of LT3 therapy. In addition, the risk of stroke was higher in LT3 users without thyroid cancer history and those who underwent ≥52 weeks of LT3 therapy. Conclusions: The use of LT3 was associated with increased incidence of heart failure and stroke in patients with a longer duration of LT3 use and history of thyroid cancer. Therefore, clinicians should consider the risk of heart failure and stroke in thyroid cancer patients with long-term use of LT3. These findings require confirmation in other populations.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Yi W, Kim BH, Kim M, et al. Heart Failure and Stroke Risks in Users of Liothyronine With or Without Levothyroxine Compared with Levothyroxine Alone: A Propensity Score-Matched Analysis. Thyroid. 2022. PMID: 35570696. doi:10.1089/thy.2021.0634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。